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A 58-year-old woman was admitted to the
hospital because of chest pain. The night before
admission, the patient awoke with crushing, non-
pleuritic chest pain radiating down her left arm,
with associated presyncope and diaphoresis. The
pain was like cardiac chest pain that she had ex-
perienced previously. She had no dyspnea, fever,
chills, or cough. She had long-standing hyper-
tension and diabetes mellitus in association with
corticosteroid therapy for idiopathic thrombocy-
topenic purpura, as well as a family history of
premature coronary artery disease. She had had
two normal pregnancies and one spontaneous
abortion. Five months before this admission, she
had been admitted because of chest pain. A di-
agnosis of acute anterior myocardial infarction
was made on the basis of electrocardiographic
changes and elevated creatine kinase levels. Car-
diac catheterization revealed total occlusion of the
proximal left anterior descending artery, which
was treated with angioplasty and stent placement.
Her hospitalization was complicated by dehis-
cence of a left groin wound and a urinary tract
infection with 
 
Escherichia coli,
 
 and she was con-
fined to bed for 10 weeks.
 
This history is suggestive of myocardial ischemia.
The patient has pain like that associated with a pre-
vious infarction, and has recently undergone coro-
nary angioplasty and stent placement. Myocardial
infarction or unstable angina from closure at the
stent site is a likely possibility, especially because
about 30 percent of occluded vessels treated with
angioplasty become reoccluded within six months.
Dressler’s syndrome, or postinfarction pericarditis,
can present with this type of chest pain, but the pa-
tient’s use of corticosteroids and the absence of sys-
temic symptoms make this diagnosis less likely. Aor-
tic dissection can also mimic myocardial infarction
and should be considered in a patient with hyper-
tension and vascular disease. Confinement to bed in-
creases the risk of pulmonary embolism, but the pa-
tient had no dyspnea or hemoptysis, and her chest
pain was not pleuritic. Pneumothorax, pneumonia,
and abdominal processes such as pancreatitis and
perforating ulcer are not compelling possibilities with
this history, but they should be kept in mind. I
would focus on physical findings of aortic dissection
and pericarditis, because the management of these
disorders differs substantially from the management
of myocardial infarction. I would also like to see a
chest film and an electrocardiogram.
 
On examination, the patient had a cushingoid
appearance; she was not in acute distress. Her
blood pressure was 120/70 mm Hg in both
arms, her pulse was 80 beats per minute and reg-
ular, her respirations were 16 per minute, and
her temperature was 36.4°C. She had numerous
petechiae in her mouth, a hemorrhagic bulla on
her tongue, and bilateral xanthelasma. There was
no jugular venous distention or carotid bruit,
and the findings were normal on auscultation of
the lungs and heart. There were no friction rubs
or murmurs of aortic regurgitation. The abdo-
men was soft and nontender, with no pulsatile
mass. There was a well-healed splenectomy scar.
There was a stage I sacral decubitus ulcer and a
healing left groin wound containing granulation
tissue. Numerous ecchymoses were present on all
the extremities. The pulses were equal and sym-
metric in all the extremities. An electrocardio-
gram, which revealed sinus rhythm and evidence
of an old anterior infarction, was unchanged from
a previous postinfarction electrocardiogram. A
chest film showed clear lungs and no mediastinal
widening.
 
Aortic dissection is less likely but is not ruled out
by the normal chest film, symmetric pulses, and ab-
sence of aortic regurgitation on physical examina-
tion. Although the history is suggestive of recurrent
myocardial ischemia, there is no electrocardiographic
or laboratory evidence of an unstable coronary syn-
drome, unless the patient has electrocardiographical-
ly silent ischemia. My index of suspicion for ischemia
remains high, although I have not thoroughly inves-
tigated other items on my original differential diag-
nosis. I would begin treatment with a beta-blocker,
but I would not give her aspirin or heparin, since she
has idiopathic thrombocytopenic purpura and overt
bleeding.
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Values for cardiac enzymes, electrolytes, renal
function, liver function, prothrombin time, and
activated partial-thromboplastin time were nor-
mal. The white-cell count was 7900 per cubic
millimeter, the hematocrit was 33.7 percent, and
the platelet count was 24,000 per cubic millime-
ter (base-line value, 60,000 per cubic millimeter
during treatment with 4 mg of dexamethasone
per day). Arterial-blood gas values while the pa-
tient was receiving 4 liters of oxygen per minute
were as follows: pH, 7.50; partial pressure of car-
bon dioxide, 38 mm Hg; and partial pressure of
oxygen, 89 mm Hg.
 
The elevated alveolar–arterial gradient increases
the likelihood of pulmonary embolism, even in the
absence of pleuritic chest pain, dyspnea, and tachy-
cardia. I would obtain a lung scan immediately. Be-
cause the patient has active bleeding and thrombo-
cytopenia, I would not treat her with anticoagulants
until I was convinced that she had pulmonary em-
bolism.
 
Ventilation–perfusion scanning showed a single
large perfusion defect in the left upper lobe with-
out a matching ventilation defect. The finding
was interpreted as indicating an “intermediate
probability” of pulmonary embolism. Duplex ul-
trasonography of the lower extremities was nor-
mal. Intravenous heparin treatment was started.
The patient’s platelet count, obtained six hours
later, was 4000 per cubic millimeter, and the pa-
tient had epistaxis and worsening ecchymoses on
her extremities. Urine culture and two sets of
blood cultures were all positive for 
 
E. coli,
 
 and in-
travenous antibiotics were administered.
 
Her infection has probably worsened the throm-
bocytopenia and triggered bleeding, and now there
is a risk of a catastrophic hemorrhage. Because of the
high risk of bleeding, I would worry considerably
about giving her heparin. Lung scans indicating an
intermediate probability of embolism have a moder-
ate false positive rate, and in view of the normal find-
ings on leg ultrasonography, I believe it is essential
to obtain a pulmonary angiogram. We should not
forget that thrombi can form despite severe throm-
bocytopenia. I would also treat her with intravenous
immune globulin for the thrombocytopenia.
 
Pulmonary angiography was performed with-
out complications, and a clot in the anterior seg-
ment of the left upper lobe was found. Other lab-
oratory results obtained before initiating therapy
with heparin included a dilute-Russell’s-viper-
venom time of 37.3 seconds (normal range, 21.4
to 36.2) and a positive test for IgG anticardiolip-
in antibody. The results of tests for protein C,
protein S, and antithrombin III were normal; a
test for antibody to the human immunodeficien-
cy virus and a polymerase-chain-reaction assay
for the factor V Leiden mutation were negative.
A review of her medical records from another
hospital did, however, reveal a history of deep
venous thrombosis the previous year. Treatment
with warfarin resulted in anticoagulation without
further bleeding, and heparin was discontinued.
Several days after the initiation of treatment with
intravenous immune globulin and antibiotics, her
platelet count increased to more than 200,000
per cubic millimeter, and she had no clinically ev-
ident episodes of bleeding or clotting.
 
COMMENTARY
 
Pulmonary thromboembolism accounts for up to
250,000 hospitalizations and 50,000 deaths each
year in the United States.
 
1
 
 Only one third of emboli
confirmed at autopsy are diagnosed before death,
 
2,3
 
reflecting the difficulty of establishing the diagnosis.
Since the 1960s, there has been no significant re-
duction in mortality from pulmonary embolism,
 
4
 
despite the widespread use of lung scanning and an-
giography.
 
5,6
 
 The experience with this patient under-
scores the importance of a high index of clinical sus-
picion and a rational approach to testing.
The patient presented with chest pain that was like
the pain associated with a previous myocardial in-
farction in the context of confinement to bed and
active idiopathic thrombocytopenic purpura. The in-
dex of suspicion for recurrent myocardial ischemia
was high because 30 percent of occluded coronary
vessels become reoccluded within six months after
angioplasty.
 
7
 
 Even so, the discussant thoughtfully
formulated a differential diagnosis that included vas-
cular, pericardial, pulmonary, and gastrointestinal
processes. The initial evaluation focused on signs of
aortic dissection and pericarditis, since the usual ap-
proaches to the treatment of myocardial infarction
— anticoagulation, thrombolysis, or angioplasty —
would be hazardous in the presence of these disor-
ders. However, the discussant found no evidence of
an unstable coronary syndrome, aortic dissection,
pneumothorax, or pneumonia.
It is critical to have a high index of suspicion for
pulmonary emboli in a patient with unexplained re-
cent chest pain, dyspnea, or tachypnea. Palla and
colleagues
 
8
 
 showed that the presence of any one of
these symptoms, without an obvious explanation in-
dicated by the findings on a routine chest film and
electrocardiogram, has a sensitivity of 97 percent
and a specificity of 24 percent for detecting pulmo-
nary embolism. This initial emphasis on diagnostic
sensitivity minimizes the possibility of a missed di-
agnosis, since clinical criteria alone are notoriously
unreliable in establishing the diagnosis. Indeed, the
patient had none of the findings known to be spe-
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cific for pulmonary emboli, such as pleuritic chest
pain,
 
9
 
 sudden dyspnea,
 
9
 
 tachypnea,
 
10,11
 
 hemoptysis,
 
12
 
and jugular-vein distention.
 
9
 
 Instead, less specific
features were present, including a history of confine-
ment to bed (reported in 55 percent of patients with
pulmonary embolism), nonpleuritic chest pain (re-
ported in 14 percent), and diaphoresis (reported in
27 percent).
 
12
 
 The chest film, which is abnormal
in more than 80 percent of patients,
 
9
 
 was normal in
our patient. The most common electrocardiographic
abnormalities in patients with pulmonary embolism,
sinus tachycardia (in 44 percent of patients)
 
9
 
 and
nonspecific ST depression (in 50 percent), were
both absent in our patient. By maintaining a high
clinical index of suspicion for pulmonary embolism,
with an initial emphasis on diagnostic sensitivity, the
discussant considered the correct diagnosis from the
start.
A definitive diagnosis of pulmonary embolism was
established through standard radiologic evaluation.
 
13,14
 
Ventilation–perfusion scanning, the initial step, was
interpreted as indicating an intermediate probability
of embolism, but because approximately 30 percent
of patients with this kind of result have pulmonary
emboli,
 
5
 
 venous ultrasonography was performed and
revealed no thrombus. Hull and colleagues
 
6
 
 report-
ed that ambulatory, clinically stable patients with
suspected pulmonary embolism and nondiagnostic
lung scans do well without anticoagulation therapy
if serial, noninvasive leg tests are negative. However,
because the patient had another predisposing factor
(confinement to bed), a pulmonary angiogram, the
reference standard, was obtained, and a thrombus
was documented.
Was it inappropriate to expose a patient with ac-
tive bleeding to the dangers of angiography? A pre-
vious Clinical Problem-Solving article
 
15
 
 examined the
potential harm of invasive procedures and the risks
of empirical treatment in the face of diagnostic un-
certainty. The particular case involved a patient with
typical features of the hypereosinophilic syndrome,
at least in retrospect. Numerous invasive tests were
performed to rule out cancer before corticosteroid
therapy was initiated. The authors concluded that
the diagnostic certainty was reasonably high and the
risk of empirical therapy was not considerably great-
er than that of further evaluation. In our patient,
however, the diagnostic certainty was low, because
the combination of severe thrombocytopenia, active
bleeding, an equivocal lung scan, and a negative leg
ultrasound study did not support the diagnosis of
pulmonary embolism. Although thrombi can form
without platelets,
 
16
 
 the discussant believed that em-
pirical anticoagulation therapy posed an unaccept-
able risk of catastrophic hemorrhage.
 
9
 
 Hence, the
one-time risk of angiography, although nontrivial,
was justifiable, because it provided a definitive and
timely diagnosis in this hemostatic predicament. In
the future, noninvasive imaging methods such as spi-
ral computed tomography
 
17
 
 and magnetic resonance
angiography
 
18
 
 may be useful in these types of cases,
but this clinical situation merited the diagnostic
gold standard.
Once angiography confirmed the presence of a
thrombus, the next decision was whether to treat the
patient with anticoagulants or place an inferior vena
cava filter. At first glance, the patient’s active idio-
pathic thrombocytopenic purpura and concomitant
pulmonary embolism appeared to be clear indica-
tions for the placement of a filter. Inferior vena cava
filters, which help prevent pulmonary embolization
of thrombi distal to the inferior vena cava, are often
used in patients with overt bleeding from anticoag-
ulants, those likely to have bleeding with anticoagu-
lants, and those in whom anticoagulation fails; such
filters are also used for prophylaxis against thrombo-
embolism in patients with limited cardiopulmonary
reserve.
 
13,19
 
 Although these devices are used fre-
quently, there are few studies of their efficacy and
safety. In a recent randomized clinical trial,
 
20
 
 the
presence of filters in patients with deep venous
thrombosis reduced the rate of pulmonary embo-
lism in the first 12 days of treatment but did not af-
fect the mortality rate at 2 years. Moreover, filters
were associated with an excessive rate of deep venous
thrombosis. Temporary, removable filters are still un-
der investigation and may eventually offer attractive
alternatives in patients such as ours, because they
may provide the short-term benefit of caval inter-
ruption without the long-term risks demonstrated
by this trial.
The patient was treated with intravenous unfrac-
tionated heparin, which is standard therapy for acute
venous thromboembolism in North America. This
practice may soon change, because two recent clin-
ical trials
 
21,22
 
 and a meta-analysis
 
23
 
 concluded that
subcutaneous low-molecular-weight heparins were
at least as safe and effective as intravenous unfrac-
tionated heparin in the treatment of acute venous
thromboembolism. Low-molecular-weight heparins
also produce more predictable anticoagulation
 
24
 
 and
are less likely to cause thrombocytopenia,
 
25
 
 both of
which were considerations in this patient. Immedi-
ately after the initiation of treatment with unfrac-
tionated heparin, the patient’s thrombocytopenia wor-
sened, probably because of worsening urosepsis and
idiopathic thrombocytopenic purpura, not heparin-
induced thrombocytopenia, which typically develops
five or more days after treatment is initiated.
 
25
 
 Even if
the patient had had true heparin-induced thrombo-
cytopenia, low-molecular-weight heparin would have
been contraindicated because of cross-reactivity be-
tween the two forms.
 
26
 
 Thus, the heparin therapy
was continued to treat the venous thromboembo-
lism; intravenous immune globulin and antibiotics
were administered to combat the idiopathic throm-
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bocytopenic purpura and urosepsis, the two main
causes of the thrombocytopenia.
The final variable that affected this patient’s treat-
ment was documentation of the antiphospholipid
syndrome. Multiple thromboembolic events in a
patient with idiopathic thrombocytopenic purpura
prompted an evaluation for thrombophilia, the for-
mation of recurrent thrombi. Congenital deficien-
cies of protein C, protein S, and antithrombin III,
as well as the presence of the factor V Leiden muta-
tion, have been associated with thrombophilia, but
these abnormalities were not present in our patient.
Her pregnancy history, however, was consistent with
the presence of the antiphospholipid syndrome, and
the elevated anticardiolipin-antibody titer and pro-
longed dilute-Russell’s-viper-venom time confirmed
the diagnosis.
 
27
 
 Both recurrent arterial thrombosis
 
28
 
and recurrent venous thrombosis
 
29
 
 are associated with
the antiphospholipid syndrome, even in the presence
of severe thrombocytopenia.
 
16
 
 Thus, the patient’s
major risk factors for thrombosis appear to have
been the antiphospholipid syndrome and confine-
ment to bed. Thrombosis in such patients is best
prevented with warfarin therapy, with the interna-
tional normalized ratio at or above 3,
 
28
 
 which was
the treatment used in this case.
Like many cases, this one hardly fit the neat algo-
rithms delineated in textbooks and clinical practice
guidelines. What lessons can we learn from this case?
First, chest pain in a patient with pulmonary embo-
lism can have an unusual presentation, so unex-
plained chest pain merits at least a consideration of
the possibility of thromboembolism. Second, pul-
monary angiography may be necessary to confirm
the diagnosis. In this patient, the results were invalu-
able in justifying the risk of anticoagulation therapy.
Third, sepsis causes thrombocytopenia. Fourth, mul-
tiple risk factors often contribute to the develop-
ment of venous thromboembolism. Finally, better
therapies are needed in the treatment of venous
thromboembolism in patients at high risk for bleed-
ing. Despite the multiple causes and consequences
of hemostatic compromise, an appropriate diagnos-
tic approach coupled with careful clinical judgment
allowed the discussant to maneuver through thick
and thin in addressing our patient’s clotting and
bleeding.
 
We are indebted to the Barker medical house staff of Johns Hop-
kins Hospital for their diligence in providing care for the patient.
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